myirislogo
19 December, 2014 12:41 IST
My Last 5 Scrips
Company BSE Price (Rs) % Chg
State Bank O 307.00 1.64
Icici Bank 353.50 2.40
Tata Stl 408.85 3.91
Infosys 1994.10 1.41
Hindalco In 157.10 2.28
Clear All Clear Last
   
NSE Live
Nifty Live Prices
Top Gainers/Losers
Top 10 Turnover
No Delivery Stocks
Advances / Declines new
Index Weightage new
Exchange Holidays new
Nse Sectors new
Contribution To Index new
Bonus new
Rights new
Delisted-Shares new
Split of Value new
BSE Live
BSE30 Live Prices
Top Gainers/Losers
Top 10 Turnover
No Delivery Stocks
Advances / Declines new
Index Weightage new
Exchange Holidays new
Bse Sectors new
Contribution To Index new
Bonus new
Rights new
Delisted-Shares new
Split of Value new
Market Pulse
Leaders
Laggards
FII Activity
Mutual Fund Activity
Meetings
Results Watch
Results Calendar
Results Announced
Watch
Sector Watch
Economy Watch
Company
Snapshots
Quotes
Charts
Financials
Recent News
Broker Research
Meetings
Research Tutorial
Research
Research Reports
Snapshot-Aurobindo Pharma Limited
Aurobindo Pharma Limited
Sector:Pharmaceuticals Pharmaceuticals - Bulk Drugs
BSE:524804NSE:AUROPHARMABloomberg:ARBP@INReuters:ARBN.BO
Market Lot: 1Face Value: 1ISIN Demat: INE406A01037
QuotesSnapshotChartsFinancialsResearchRecent News
Peer GroupAGM/AMMF HoldingDiscussion ForumBSE/NSE NoticesBSE/NSE Deals

 
 
Recent Developments
11-DEC-14 Aurobindo Pharma, a mid-size pharmaceutical company, announced that the board of directors of the company at its meeting held on Wednesday, have resolved subject to the approval of the members of the company in terms 05-DEC-14 Aurobindo Pharma today announced the completion of acquisition of assets of nutritional supplement maker, Natrol and other affiliate entities through its wholly owned subsidiary Aurobindo Pharma USA (APUSA). ...   More..
Business Profile Future Plans
CEO Talk
Aurobindo Pharma, plans to complete restructuring and expansion programme during Q4 FY 2001-02. The company plans to achieve a turnover of above Rs 4,000 crore by FY 2005-06 with formulations accounting for 30 per cent. Joint ventures in US and China are expected boost the company`s international revenues.  Srinivas Lanka
One To One
Recent news
Latest News
Aurobindo Pharma board approves raising funds via QIP  -IRIS 11-Dec-14
Previous

More


Brief Financials (in Rs. Mn.)Detailed Quarterly
Period ending (months)30-Sep-2014(6)31-Mar-2014 (12)31-Mar-2013 (12)
Net sales 39232.2070495.7053529.10
Other Income243.40328.70150.10
Total Income39475.6070824.4053679.20
Cost of goods sold28162.9051912.3044670.40
OPBDIT11312.7018912.109008.80
PAT7850.6011720.904959.90
Gross Block---
Equity capital291.50291.50291.20
EPS (Rs.)-40.2417.04
DPS (Rs.)---
BV (Rs.)---
P/E range (x)-3.44 - 13.545.85 - 12.02
Debt / Equity (x)---
Operating margin (% of OI)28.726.716.8
Net margin (% of OI)19.916.5 9.2
Detailed Financials
Income 
Statement
Balance Sheet Latest 
Quarterly/Halfyearly
Ratio Analysis Share Statistics
Price Charts
Scrip Information



Registered Office
ADDRESS
Plot No 2
Maitri Vihar
Ameerpet
Hyderabad
Andhra Pradesh-500 038
PHONE
(040) 6672 5000
FAX
(040) 2374 1080/ 6833
 
Board of Directors
NSE/BSE Announcements


Home | Shares | F&O | Mutual Funds | Loans | Insurance | News Centre
Wealth Tracker | Tax Corner | NRI Centre | Search in myiris | Advertise
All rights reserved. IRIS Business Services Limited
Disclaimer